Costs versus benefits: Best possible and best practical treatment regimens for HIV

Journal of Mathematical Biology

Volumn 54, Issue 3, 2007, Pages 385-406

  Krakovska, O ^a   Wahl, L M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Drug treatment; HAART; Human immunodeficiency virus; Mathematical model; Optimization; Resistance; Side effects

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOLOGICAL MODEL; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COST BENEFIT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MODELS, IMMUNOLOGICAL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33847353448     PISSN: 03036812     EISSN: 14321416     Source Type: Journal    
DOI: 10.1007/s00285-006-0059-1     Document Type: Article

References (47)

1. Adams, B.M., Banks, H.T., Davidian, M., Kwon, H.D., Tran, H.T., Wynne, S.N.: HIV dynamics: modeling, data analysis, and optimal treatment protocols. J. Comput. Appl. Math. 184(1), 10-49 (2004)
2. Adams, B.M., Banks, H.T., Tran, H.T., Kwon, H.: Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng. 1, 223-241 (2004)
3. Bajaria, S.H., Webb, G., Kirschner, D.E.: Predicting differential responses to structured treatment interruptions during HAART. Bull. Math. Biol. 66(5), 1093-1118 (2004)
4. Boffito, M., Back, D.J., Blaschke, T.F., Rowland, M., Bertz, R.J., Gerber, J.G., Miller, V.: Protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses 19(9), 825-835 (2003)
5. Bonhoeffer, S., May, R.M., Shaw, G.M., Nowak, M.A.: Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94, 6971-6976 (1997)
6. Bonhoeffer, S., Nowak, M.A.: Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. R. Soc. Lond. B Bio. 264(1382), 631-637 (1997)
7. Bonhoeffer, S., Rembiszewski, M., Ortiz, G.M., Nixon, D.F.: Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS 14(15), 2313-2322 (2000)
8. Butler, S., Kirschner,D., Lenhart, S.: Optimal control of chemotherapy affecting the infectivity of HIV. In: Arino, O., Axelrod, D., Kimmel, M., Langlais, M. (eds.) Advances in Mathematical Population Dynamics: Molecules, Cells, Man, pp. 104-120. World Scientific Publishing, (1997)
9. Cavert, W., Notermans, D.W., Staskus, K., Wietgrefe, S.W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z.Q., Mills, R., McDade, H., Schuwirth, C.M., Goudsmit, J., Danner, S.A. , Haase, A.T.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276(5314), 960-964 (1997)
10. Chun, T.W., Fauci, A.S.: Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. USA 96(20), 10958-10961 (1999)
11. Culshaw, R.V., Ruan, S., Spiteri, R.J.: Optimal HIV treatment by maximising immune response. J. Math. Biol. 48(5), 545-562 (2004)
12. + T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171(8), 3928-3935 (2003)
13. Dorman, K.S., Kaplan, A.H., Lange, K., Sinsheimer, J.S.: Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?. J. Acq. Imm. Defic. Syndr. 25(5), 398-402 (2000)
14. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512-517 (1999)
15. Fister, K.R., Lenhart, S., McNally, J.S.: Otimizing chemotherapy in an HIV model. Electr. J. Diff. Eq. 32, 1-12 (1998)
16. Frost, S.D.: Dynamics and evolution of HIV-1 during structured treatment interruptions. AIDS Rev. 4(3), 119-127 (2002)
17. Frost, S.D., Martinez-Picado, J., Ruiz, L., Clotet, B., Brown, A.J.: Viral dynamics during structured treatment interruptions of chronic Human Immunodeficiency Virus type 1 infection. J. Virol. 76(3), 968-987 (2002)
18. Funk, G.A., Fischer, M., Joos, B., Opravil, M., Gunthard, H.F., Ledergerber, B., Bonhoeffer, S.: Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J. Acquir. Immune. Defic. Syndr. 26(5), 397-404 (2001)
19. HIV ePharmacotherapy Network Home page. http://hiv.buffalo.edu. Cited 22, 2005
20. Jeffrey, A.M., Xia, X., Craig, J.K.: When to initiate HIV therapy: a control theoretic approach. IEEE Trans. Biomed. Eng. 50(11), 1213-1219 (2003)
21. Joshi, H.R.: Optimal control of an HIV immunology model. Optim. Contr. Appl. Math. 4, 199-213 (2002)
22. Julg, B., Goebel, F.D.: Treatment interruption in HIV therapy: a SMART strategy? Infection 34(3):186-188 (2006)
23. Kaech, S.M.,Wherry, E.J., Ahmed, R.:Effector andmemory T cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2(4), 251-262 (2002)
24. Kirschner, D., Lenhart, S., Serbin, S.: Optimizing chemotherapy of HIV infection: scheduling, amounts and initiation of treatment. J. Math. Biol. 35, 775-792 (1997)
25. Kirschner, D., Webb, G.F.: Amodel for treatment strategy in the chemotherapy of AIDS. Bull. Math. Biol. 58(2), 367-390 (1996)
26. Komarova, N.L., Barnes, E., Klenerman, P., Wodarz, D.: Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success. Proc. Natl. Acad. Sci. USA 100(4), 1855-1860 (2003)
27. Kutch, J.J., Gurfil, P.: Optimal control of HIV infection with a continuously-mutating viral population. In: Proceedings of American Control Conference, pp. 4033-4038 (2002)
28. + cell counts, and HIV-1 production by cells. Science 271(5249), 670-671 (1996)
29. Mansky, L.M., Temin, H.M.: Lower in vivo mutation rate of Human Immunodeficiency Virus Type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69(8), 5087-5094 (1995)
30. Markowitz, M., Louie, M., Hurley, A., Sun, E., Di Mascio, M., Perelson, A.S., Ho, D.D.: A novel antiviral intervention results in more accurate assessment of Human Immunodeficiency Virus Type 1 replication dynamics and T cell decay in vivo. J. Virol. 77, 5037-5038 (2003)
31. Mohri, H., Perelson, A.S., Tung, K., Ribeiro, R.M., Ramratnam, B., Markowitz, M., Kost, R., Hurley, A., Weinberger, L., Cesar, D., Hellerstein, M.K., Ho, D.D.: Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194(9), 1277-1287 (2001)
32. Murphy, R.L., Sommadossi, J.P., Lamson, M., Hall, D.B., Myers, M., Dusek, A.: Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with Human Immunodeficiency Virus type 1. J. Infect. Dis. 179(5), 1116-1123 (1999)
33. NIAD Division of AIDS (DAIDS)Home page. http://www.niaid.nih.gov/daids/. Cited 22, 2005
34. Nowak, M.A., May, R.M.: Virus Dynamics: Mathematical Principles of Immunology and Virology, Chap. 10. Oxford University Press, Oxford, New York (2000)
35. Pfizer Inc. Home page. http://www.pfizer.ca/. Cited 22, 2005
36. Ramratnam, B., Mittler, J.E., Zhang, L., Boden, D., Hurley, A., Fang, F., Macken, C.A., Perelson, A.S., Markowitz, M., Ho, D.D.: The decay of the latent reservoir of replicationcompetent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6(1), 82-85 (2000)
37. + T cells depleted?. Proc. Natl. Acad. Sci. USA 99(24), 15572-15577 (2002)
38. Richman, D.D.: The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res. 29(1), 31-33 (1996)
39. RxList, The Internet Drug Index Home page. http://www.rxlist.com/. Cited 15 October 2005
40. Stengel, R.F., Ghigliazza, R.: Stochastic optimal therapy for enhanced immune response. Math. Biosci. 191, 123-142 (2004)
41. The Immunodeficiency Clinic-University Health Network Home Page. http://www.tthhivclinic.com/. Cited 15 October 2005
42. van Heeswijk, R.P., Veldkamp, A.I., Mulder, J.W., Meenhorst, P.L., Wit, F.W., Lange, J.M., Danner, S.A., Foudraine, N.A., Kwakkelstein, M.O., Reiss, P., Beijnen, J.H., Hoetelmans, R.M.: The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1 infected individuals. AIDS 14(8), F77-F82 (2000)
43. Wahl, L.M., Nowak, M.A.: Adherence and resistance: Predictions for therapy outcome. Proc. Biol. Sci. 267(1445), 835-843 (2000)
44. Walensky, R.P., Goldie, S.J., Sax, P.E., Weinstein, M.C., Paltiel, A.D., Kimmel, A.D., Seage, G.R., Losina, E., Zhang, H., Islam, R., Freedberg, K.A.: Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J. Acquir. Immune. Defic. Syndr. 31, 27-37 (2002)
45. Wein, L.M., Zenios, S.A., Nowak, M.A.: Dynamic multidrug therapies for HIV: a control-theoretic approach. J. Theor. Biol. 185, 15-29 (1997)
46. Wodarz, D., Page, K.M., Arnaout, R.A., Thomsen, A.R., Lifson, J.D., Nowak, M.A.: A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355(1395), 329-343 (2000)
47. + memory T cell generation. J. Immunol. 173(6), 3763-3772 (2004)